Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria. This data compares favorably with data from a published study showing an objective tumor response rate of 41% in a similar patient population receiving the same dosing regimen of docetaxel administered as a single agent.

Joseph Shan, vice president of clinical and regulatory affairs at Peregrine commented, "We are very encouraged by the initial results reported today for the full 46 patients enrolled in the bavituximab plus docetaxel Phase II trial. The tumor response data reported in this study exceeded the tumor response data for docetaxel alone that was used as the benchmark for the design of this study. With these positive initial data in hand, we and our expert advisors believe that this combination regimen warrants further clinical evaluation, and we are now assessing possible trial designs for future studies."

The primary objective of the multi-center, open-label Phase Il study is to assess the overall response rate to bavituximab and docetaxel. In this trial's Simon two-stage design, 15 patients were initially enrolled in the study followed by an additional 31 patients after the pre-specified primary efficacy endpoint for expanding the study was met, bringing the total to 46 patients. Initial data from the first set of 15 patients in the study was reported in an oral presentation at the 2009 ASCO Annual Meeting. Recent analysis showed the median progression-free-survival (PFS) of patients enrolled in the initial 15-patient cohort of the study was 7.4 mo
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... Canada, Key Trends and Opportunities to 2017 ... Synopsis The report provides in ... the Canadian personal accident and health insurance ...
(Date:8/20/2014)... , Aug. 20, 2014 Children ... can receive vaccinations to help prevent disease. The ... vaccination for all adults, but currently, many adults ... August is National Immunization Awareness Month, and the ... urging adults, especially those with lung disease, to ...
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ... Kalorama Information,s Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ...
Breaking Medicine Technology:Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12
... , , , , ... Aug. 17 The US Food and Drug Administration (FDA) has approved ... sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. ... for the treatment of relapsing forms of MS to reduce the frequency ...
... WA and VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the first patient has been dosed in an open ... administered directly into the bladder in patients with bladder ... 1 trial of OGX-427 administered systemically in patients with ...
Cached Medicine Technology:US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 2US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 3US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 5US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 6US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 7OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 2OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 3OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer 4
(Date:8/20/2014)... By Dennis Thompson ... -- A new experimental drug has saved a group of ... of Ebola virus that kills up to 90 percent of ... monkeys infected with lethal doses of Marburg virus, even when ... study published Aug. 20 in the journal Science Translational ...
(Date:8/20/2014)... discovered that the immune system is defective in people suffering ... sufferers have ongoing issues with pain. , The research ... also help to explain why some painkillers may not offer ... up to 10% of the community. There are different ... pain, which often has the greatest impact on sufferers, quality ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Loss of brain cells that ... many seniors have trouble falling and staying asleep, a ... can be especially severe and often results in nighttime ... investigators analyzed data from the Rush Memory and Aging ... age 65 and are being followed until death, at ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
Breaking Medicine News(10 mins):Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Pain treatments less effective for those with irritable bowel 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3
... , FRIDAY, Oct. 29 (HealthDay News) -- ... serious and chronic bouts of constipation, according to experts. ... consumption of water may be contributing to the problem, ... reported seeing a 30 percent rise in the number ...
... disease is being investigated in research led at the ... Trypanosomiasis, also known as sleeping sickness, affects between 50,000 ... is transmitted through the bite of the tsetse fly ... fever, headaches and disturbed sleep patterns. Without treatment, ...
... kidney failure patients in the United States are twice as likely ... although the likelihood is still low, a new studyfinds. About ... and 48 percent of them are 60 or older. The ... of the American Society of Nephrology , included kidney failure patients, ...
... GABLES, FL (October 28, 2010)To help unravel the mysteries ... in robotics, University of Miami (UM) developmental psychologists and ... Diego (UC San Diego) are studying infant-mother interactions and ... capable of learning social skills. The first phase ...
... from Mount Sinai School of Medicine have identified a ... to DNA during embryonic development and may function to ... modified by a small molecule called a phosphate, it ... signals during development. This discovery identifies a new diagnostic ...
... Oct. 28 (HealthDay News) -- The rate of new cases ... diabetes fell 35 percent between 1996 and 2007, a new ... disease, also known as end-stage renal disease (ESRD), that was ... 100,000 people during that time. The declining rates occurred in ...
Cached Medicine News:Health News:Chronic Constipation Appears to Be Increasing Among Kids 2Health News:UM researchers are studying child-mother interactions to design robots with social skills 2Health News:Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer 2Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Medicine Products: